NEXTCURE INC (NXTC) Stock Price, Forecast & Analysis
NASDAQ:NXTC • US65343E2072
NXTC Key Statistics, Chart & Performance
The current stock price of NXTC is 13.24 USD. In the past month the price increased by 2.16%. In the past year, price increased by 45.69%.
NXTC Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to NXTC. When comparing the yearly performance of all stocks, NXTC is one of the better performing stocks in the market, outperforming 90.63% of all stocks.
NXTC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NXTC. NXTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NXTC Financial Highlights
Over the last trailing twelve months NXTC reported a non-GAAP Earnings per Share(EPS) of -24.11. The EPS increased by 3.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.44% | ||
| ROE | -245.33% | ||
| Debt/Equity | 0 |
NXTC Forecast & Estimates
9 analysts have analysed NXTC and the average price target is 18.02 USD. This implies a price increase of 36.1% is expected in the next year compared to the current price of 13.24.
NXTC Ownership
NXTC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 390.397B | ||
| AMGN | AMGEN INC | 16.25 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.85 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NXTC
Company Profile
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 43 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Company Info
NEXTCURE INC
9000 Virginia Manor Rd Ste 200
Beltsville MARYLAND 20705 US
CEO: Michael Richman
Employees: 43
Phone: 12403994900
NEXTCURE INC / NXTC FAQ
What does NEXTCURE INC do?
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 43 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
What is the stock price of NEXTCURE INC today?
The current stock price of NXTC is 13.24 USD. The price increased by 5.92% in the last trading session.
Does NXTC stock pay dividends?
NXTC does not pay a dividend.
What is the ChartMill technical and fundamental rating of NXTC stock?
NXTC has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting NXTC stock to perform?
9 analysts have analysed NXTC and the average price target is 18.02 USD. This implies a price increase of 36.1% is expected in the next year compared to the current price of 13.24.
How is the valuation of NEXTCURE INC (NXTC) based on its PE ratio?
NEXTCURE INC (NXTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-24.11).
Can you provide the ownership details for NXTC stock?
You can find the ownership structure of NEXTCURE INC (NXTC) on the Ownership tab.